Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-018-2930-5
Abstract: IntroductionBrain metastases are common in metastatic melanoma and radiosurgery is often utilized for local control. Immune checkpoint inhibitors (CPIs) play a central role in contemporary melanoma management; however, there is limited data exploring outcomes and… read more here.
Keywords: melanoma; immune checkpoint; cns progression; newly diagnosed ... See more keywords
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Targeted Oncology"
DOI: 10.1007/s11523-020-00702-4
Abstract: Background Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood–brain barrier. Objective We report the cumulative incidence of central nervous system (CNS) and non-CNS progression with lorlatinib in patients… read more here.
Keywords: progression; cns progression; cns non; non cns ... See more keywords
1337 The Impact of Brain Metastasis Multiplicity on Postoperative Survival and CNS Progression: A Single Center Study
Sign Up to like & getrecommendations! Published in 2025 at "Neurosurgery"
DOI: 10.1227/neu.0000000000003360_1337
Abstract: INTRODUCTION: The prognosis of patients with brain metastasis (BM) depends on patient and disease-specific factors. Intracranial disease burden may be associated with postoperative outcomes such as survival and CNS tumor progression, although the extent of… read more here.
Keywords: survival; time; cns progression; progression ... See more keywords